Flibanserin (Addyi): Mechanism, Clinical Evidence, and How It Actually Works

Does Flibanserin Come in an Injectable Form?

Flibanserin does not exist in any injectable, subcutaneous, intramuscular, or intravenous formulation. It is supplied exclusively as a 100 mg oral immediate-release tablet. Any content claiming a "flibanserin self-injection technique" is factually incorrect. The FDA-approved label, reviewed in the accessdata.fda.gov database, lists only the oral route. [1]

If you arrived at this page searching for a self-injection technique because you read about it elsewhere, stop before purchasing or attempting any injectable product marketed as flibanserin. No such product has passed FDA review, and injecting a compound designed for oral bioavailability carries serious risks including infection, embolism, and systemic toxicity.

Why the Confusion Exists

Online compounding pharmacies and gray-market peptide vendors occasionally list "flibanserin injection" or "PT-141 / flibanserin blend" vials. PT-141 (bremelanotide) is a separate FDA-approved drug for HSDD given as a subcutaneous injection. [2] These are chemically distinct molecules. Mixing them, or injecting oral flibanserin powder, has no clinical evidence base and no regulatory approval.

The Correct Administration Method

Take one 100 mg tablet at bedtime. Taking it during waking hours substantially increases hypotension and syncope risk due to the drug's alpha-1 adrenergic antagonism. The FDA mandated a Risk Evaluation and Mitigation Strategy (REMS) program precisely because of that interaction profile. [1]

What Is Flibanserin and What Condition Does It Treat?

Flibanserin is a small-molecule drug approved by the FDA on August 18, 2015, for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. [1] HSDD is defined as persistently low sexual desire causing marked distress or interpersonal difficulty, without a more explanatory medical or psychiatric diagnosis accounting for it. [3]

The American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin No. 213 states: "HSDD is the most common female sexual dysfunction, affecting approximately 10% of adult women in the United States." [4]

Epidemiology of HSDD

Population surveys using the Female Sexual Function Index (FSFI) put the prevalence of distressing low desire between 8.9% and 12.4% in premenopausal women in the United States. [5] A 2008 analysis in Obstetrics and Gynecology (N=31,581) found that 9.0% of women aged 18 to 44 reported low desire with associated distress. [5] Before flibanserin, no FDA-approved pharmacological option existed for this population.

How HSDD Differs from Other Sexual Dysfunctions

HSDD is a disorder of desire, not arousal or orgasm. Phosphodiesterase-5 inhibitors like sildenafil act on genital blood flow and have consistently failed to improve desire outcomes in women. [6] Flibanserin targets the brain, not the genitalia, which is why its mechanism is so different from any treatment in the erectile-dysfunction class.

How Does Flibanserin Work? The Mechanism Explained

Flibanserin acts as a postsynaptic 5-HT1A full agonist and a 5-HT2A antagonist, with additional antagonism at 5-HT2B and 5-HT2C receptors and partial agonism at dopamine D4 receptors. [7] That receptor profile is sometimes described as "multifunctional" because it hits multiple nodes in the prefrontal cortex circuits that regulate sexual motivation.

Serotonin's Role in Sexual Inhibition

In the medial prefrontal cortex, serotonin (5-HT) generally exerts an inhibitory tone on sexual desire. High serotonergic activity, as seen with SSRI use, is associated with reduced libido, delayed orgasm, and anorgasmia. [8] Flibanserin's agonism at the 5-HT1A autoreceptor reduces serotonin release from raphe nuclei projections. [7] Simultaneously, its antagonism at 5-HT2A receptors on postsynaptic neurons blunts the inhibitory signal that serotonin would otherwise send.

The net result is a reduction in serotonergic inhibition of desire-related circuits. [7]

Dopamine and Norepinephrine Disinhibition

When serotonergic inhibition is reduced, dopamine and norepinephrine activity in the mesolimbic pathway increases. [7] Dopamine in this system is closely tied to motivational salience, including sexual motivation. Flibanserin's D4 partial agonism may contribute an additional direct dopaminergic signal, though this component is considered secondary to the serotonin modulation in vivo. [8]

A 2012 preclinical study in rats published in Naunyn-Schmiedeberg's Archives of Pharmacology showed that repeated flibanserin dosing increased dopamine and norepinephrine release in the prefrontal cortex while reducing serotonin levels, consistent with this dual mechanism. [8]

Why Bedtime Dosing Matters Mechanistically

The hypotension risk from flibanserin's alpha-1 adrenergic antagonism peaks within 1 to 2 hours of ingestion. Taking the drug during sleep essentially eliminates the symptomatic window for orthostatic syncope. The pharmacokinetic half-life is approximately 11 hours, meaning therapeutic CNS concentrations persist through waking hours without the cardiovascular peak coinciding with ambulation. [1]

Clinical Trial Evidence: What the Data Actually Show

BEGONIA Trial (J Sex Med 2014, N=949)

The BEGONIA trial is the most-cited phase 3 randomized controlled trial of flibanserin 100 mg at bedtime versus placebo in premenopausal women with HSDD. [9] Over 24 weeks, women in the flibanserin group reported a mean increase of 0.5 satisfying sexual events (SSEs) per month compared with the placebo group (P<0.001). The Female Sexual Function Index desire domain score improved by 1.0 point (scale 1.2 to 6.0) versus 0.7 points for placebo. [9]

The Female Sexual Distress Scale-Revised (FSDS-R) item 13 score, which measures distress specifically attributable to low desire, dropped by 0.9 points in the flibanserin arm versus 0.6 points with placebo (P<0.001). [9]

VIOLET and DAISY Trials

Two additional phase 3 trials, VIOLET and DAISY, used identical endpoints. Pooled analysis across BEGONIA, VIOLET, and DAISY (combined N=2,742 women) found a mean increase of 0.5 to 1.0 SSEs per month, an FSFI desire domain improvement of approximately 1.0 point, and a statistically significant reduction in distress on FSDS-R item 13. [10] These effect sizes are modest but statistically consistent across trials.

The FDA's own medical review document for NDA 022526 noted that the clinical meaningfulness of a half-event-per-month increase in SSEs was debated during the advisory committee process, but the agency concluded that the distress reduction data supported approval. [1]

Discontinuation Due to Adverse Events

Across the phase 3 program, 13.5% of flibanserin-treated women discontinued due to adverse events versus 5.7% in the placebo group. [10] The most common adverse events were dizziness (11.4% vs. 2.2%), somnolence (11.2% vs. 4.0%), nausea (10.4% vs. 3.9%), and fatigue (9.2% vs. 5.5%). [10]

Dosing, Titration, and Treatment Duration

The approved dose is 100 mg orally once daily at bedtime. There is no titration schedule. The drug is either taken at 100 mg or not taken at all per label. [1]

The FDA label recommends re-evaluating efficacy at 8 weeks. If no meaningful improvement in desire or reduction in distress has occurred by week 8, discontinuation is recommended because continued exposure without benefit carries ongoing adverse-event risk. [1]

What to Expect in the First 4 to 8 Weeks

Most patients who respond to flibanserin begin noticing improvement in desire and a reduction in distress-related symptoms within 4 weeks. [9] In BEGONIA, statistically significant separation from placebo on SSEs appeared at week 4 and widened through week 24. [9] Patients who see no change by week 8 are unlikely to become responders with continued use.

Long-Term Use Data

An open-label extension study of 24 additional weeks following the BEGONIA trial showed maintained efficacy without new safety signals in patients who were initial responders. [9] There are no published randomized controlled trial data beyond 52 weeks of continuous use.

The Alcohol Interaction: Why the REMS Program Exists

The FDA's REMS program for flibanserin requires prescribers to counsel every patient that alcohol must be completely avoided while taking the drug. [1] This is not a "limit alcohol" instruction. It is a complete prohibition.

A dedicated pharmacokinetic interaction study (N=25) showed that co-ingestion of flibanserin 100 mg with alcohol produced hypotension in 4 of 23 evaluable subjects (17.4%) and syncope in 2 (8.7%), compared with 0 events in the placebo-plus-alcohol arm. [1] Blood pressure nadir after the combination reached a mean systolic of 94 mmHg in affected subjects. [1]

CYP3A4 Drug Interactions

Flibanserin is primarily metabolized by CYP3A4 and, to a lesser extent, CYP2C19. [1] Co-administration with strong CYP3A4 inhibitors, including fluconazole, ketoconazole, itraconazole, clarithromycin, and ritonavir, is contraindicated because plasma flibanserin concentrations increase by 450% to 1,200% depending on the inhibitor. [1] That exposure increase dramatically amplifies the hypotension and CNS depression risks.

Moderate CYP3A4 inhibitors, including diltiazem, erythromycin, and grapefruit juice, require caution and may warrant dose adjustment discussions with the prescribing physician. [1]

Who Should Not Take Flibanserin

Per FDA labeling, flibanserin is contraindicated in: [1]

• Women who consume alcohol in any amount
• Women taking strong or moderate CYP3A4 inhibitors
• Women with hepatic impairment (any severity)
• Women who are pregnant (animal data showed embryofetal toxicity at exposures near human therapeutic levels)

Flibanserin vs. Bremelanotide (Vyleesi): Choosing Between the Two FDA-Approved Options

Bremelanotide (Vyleesi) received FDA approval in June 2019 as the second drug approved for HSDD in premenopausal women. [2] It is the injectable option for HSDD, which may explain some of the search query confusion between the two drugs.

The table below outlines the primary clinical distinctions:

| Feature | Flibanserin (Addyi) | Bremelanotide (Vyleesi) | |---|---|---| | Route | Oral tablet | Subcutaneous injection | | Dosing schedule | Daily at bedtime | As needed, 45 min before activity | | Mechanism | 5-HT1A agonist / 5-HT2A antagonist | Melanocortin receptor agonist (MC4R) | | FDA approval | August 2015 | June 2019 | | Key contraindication | Alcohol, CYP3A4 inhibitors | Cardiovascular disease, uncontrolled hypertension | | Most common AE | Dizziness, somnolence | Nausea (40%), flushing (20%) | | Effect on blood pressure | Decreases BP (hypotension risk) | Transiently increases BP |

Women with liver disease or who cannot abstain from alcohol may be better candidates for bremelanotide if their cardiovascular history permits. Women who prefer not to self-inject, or who have daily predictable low desire rather than situational low desire, are generally better matched to flibanserin. [2] [4]

Self-Injection Technique for Bremelanotide (the Correct Drug)

Since self-injection searches often land on flibanserin pages due to query overlap, a brief note on bremelanotide injection is appropriate here.

Bremelanotide comes as a 1.75 mg/0.4 mL autoinjector pen. The FDA-approved injection sites are the abdomen or thigh. [2] The injection should be given at least 45 minutes before anticipated sexual activity. The dose may not be repeated within 24 hours, and the label recommends no more than one dose per anticipated event. Injection-site reactions occurred in 22% of patients in the RECONNECT trial (N=1,247). [2]

If you or your prescriber determine bremelanotide is appropriate, your pharmacist and the manufacturer's patient support line (1-833-VYLEESI) can walk you through autoinjector technique in detail.

Monitoring and Follow-Up After Starting Flibanserin

The prescribing clinician should schedule a follow-up visit at 4 to 8 weeks to assess: [1] [4]

• Change in number of satisfying sexual events per month
• Change in distress score (FSDS-R item 13 or equivalent patient-reported measure)
• Adverse events, particularly dizziness, somnolence, and nausea
• Medication adherence and timing (bedtime vs. Other times)
• Continued abstinence from alcohol

Blood pressure monitoring is warranted at each visit given the drug's alpha-1 antagonism. Patients starting a new CYP3A4-interacting medication while on flibanserin need immediate reassessment. [1]

Discontinuation and Re-initiation

If a patient discontinues flibanserin due to adverse events or lack of efficacy and later wishes to retry, no washout period is specified in the label. Re-initiation follows the same 100 mg nightly bedtime protocol. However, a patient who failed at 8 weeks due to non-response is unlikely to respond upon re-initiation unless a contributing reversible factor (stress, new medication affecting desire, relationship change) has been addressed. [4]

Flibanserin in Clinical Context: What ACOG and ISSWSH Say

The International Society for the Study of Women's Sexual Health (ISSWSH) 2019 consensus process on HSDD pharmacotherapy states: "Flibanserin is an appropriate first-line pharmacological option for premenopausal women with acquired, generalized HSDD who do not consume alcohol and are not taking moderate-to-strong CYP3A4 inhibitors." [11]

ACOG Practice Bulletin No. 213 (2019) notes that non-pharmacological interventions, including cognitive behavioral therapy and mindfulness-based sex therapy, should be offered alongside or before pharmacological treatment. [4] The bulletin stops short of ranking flibanserin above or below psychotherapy, recommending shared decision-making based on patient preference, alcohol use, and medication burden.

A 2016 Cochrane systematic review of interventions for HSDD (14 RCTs, N=5,114) found that flibanserin produced statistically significant improvements in SSEs and desire scores but that the clinical significance remained "uncertain due to modest absolute effect sizes." [12] The review recommended head-to-head trials against psychotherapy, which have not yet been conducted.

Practical Prescribing Checklist Before Starting Flibanserin

Clinicians must complete the following steps due to the REMS requirements: [1]

1. Certify through the Addyi REMS program (addyirems.com) before prescribing.
2. Document that the patient is premenopausal.
3. Document that HSDD is acquired and generalized, not situational or lifelong.
4. Screen for alcohol use with a validated tool (AUDIT-C score of 0 recommended before prescribing).
5. Review the complete medication list for CYP3A4 inhibitors.
6. Assess hepatic function (any impairment is a contraindication).
7. Provide and document the REMS-required patient-provider agreement.
8. Schedule 8-week follow-up to assess response.

Patients must fill flibanserin only at certified pharmacies. The REMS program maintains a list of certified dispensing pharmacies at the addyirems.com portal. [1]